RIVALIN 15MG

INDICATIONS:

• Rivalin is indicated for the prevention of venous thromboembolic events (VTE)
  in adult patients undergoing elective hip or knee replacement surgery (total hip or knee arthroplasty).
• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
• Prevention of stroke and systemic embolism in adult patients with atrial fibrillation.

AVANTAGES:

• It is a newly marketed oral anticoagulant that received the 2008 Belgian Prix Galien for the most innovative drug;
• Compared to low-molecular-weight heparins, it offers superior antithrombotic efficacy and eliminates the need for subcutaneous injections or the risk of thrombocytopenia;
• Compared to coumarins, it offers a better safety profile, requires no dose titration or adjustment, and does not necessitate thrombin time monitoring;
• It has high absolute bioavailability (80–100%) at a 10 mg dose;
• The product is rapidly absorbed, with peak concentrations (Cmax) reached 2–4 hours after tablet intake;
• It is well-tolerated compared to other anticoagulants;
• An undeniable advantage of the product is its ease of use in clinical practice.